Olstein Capital Management L.P. Has $9.76 Million Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

Olstein Capital Management L.P. raised its holdings in Becton, Dickinson and Company (NYSE:BDX) by 13.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 43,000 shares of the medical instruments supplier’s stock after acquiring an additional 5,000 shares during the period. Becton, Dickinson and Company comprises 1.7% of Olstein Capital Management L.P.’s holdings, making the stock its 7th biggest holding. Olstein Capital Management L.P.’s holdings in Becton, Dickinson and Company were worth $9,755,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of BDX. State Street Corp grew its holdings in shares of Becton, Dickinson and Company by 0.8% during the 3rd quarter. State Street Corp now owns 13,953,116 shares of the medical instruments supplier’s stock valued at $3,364,096,000 after purchasing an additional 106,616 shares during the last quarter. Geode Capital Management LLC boosted its position in Becton, Dickinson and Company by 1.8% in the third quarter. Geode Capital Management LLC now owns 6,285,513 shares of the medical instruments supplier’s stock valued at $1,510,050,000 after buying an additional 111,101 shares in the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of Becton, Dickinson and Company by 9.4% during the third quarter. Massachusetts Financial Services Co. MA now owns 5,365,554 shares of the medical instruments supplier’s stock worth $1,293,635,000 after buying an additional 460,440 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Becton, Dickinson and Company by 79.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock worth $720,089,000 after buying an additional 1,317,723 shares in the last quarter. Finally, Clearbridge Investments LLC lifted its stake in shares of Becton, Dickinson and Company by 3.1% in the 2nd quarter. Clearbridge Investments LLC now owns 2,984,524 shares of the medical instruments supplier’s stock valued at $697,513,000 after acquiring an additional 89,157 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 597 shares of Becton, Dickinson and Company stock in a transaction on Friday, January 17th. The shares were sold at an average price of $236.51, for a total value of $141,196.47. Following the completion of the sale, the executive vice president now owns 5,544 shares in the company, valued at $1,311,211.44. The trade was a 9.72 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP David Shan sold 500 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total transaction of $120,000.00. Following the transaction, the executive vice president now owns 5,741 shares in the company, valued at $1,377,840. The trade was a 8.01 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 9,844 shares of company stock valued at $2,210,716. 0.36% of the stock is currently owned by insiders.

Becton, Dickinson and Company Trading Up 1.3 %

NYSE BDX opened at $243.69 on Friday. The firm has a market capitalization of $70.67 billion, a PE ratio of 41.02, a price-to-earnings-growth ratio of 1.72 and a beta of 0.39. The business’s 50-day moving average price is $228.08 and its two-hundred day moving average price is $233.00. The company has a current ratio of 1.17, a quick ratio of 0.74 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $248.42.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, beating the consensus estimate of $3.77 by $0.04. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The business had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same period in the prior year, the business posted $3.42 earnings per share. The firm’s revenue was up 6.9% on a year-over-year basis. On average, analysts expect that Becton, Dickinson and Company will post 14.42 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, December 31st. Investors of record on Monday, December 9th were issued a $1.04 dividend. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. The ex-dividend date of this dividend was Monday, December 9th. This represents a $4.16 annualized dividend and a yield of 1.71%. Becton, Dickinson and Company’s payout ratio is presently 70.03%.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Evercore ISI boosted their price objective on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Citigroup upgraded Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. Finally, StockNews.com lowered shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $283.50.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.